Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-02-24
2000-09-12
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3152
Patent
active
061178780
ABSTRACT:
The invention concerns the use of 8-phenylxanthines, 8-cyloalkylxanthines or 8- substituted xanthine derivatives to specifically modulate the physiologic role of the A2B adenosine receptor.
REFERENCES:
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4824660 (1989-04-01), Angello et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5124455 (1992-06-01), Lombardo et al.
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5565462 (1996-10-01), Eitan et al.
patent: 5593975 (1997-01-01), Cristalli
patent: 5665754 (1997-09-01), Feldman et al.
patent: 5776940 (1998-07-01), Daluge et al.
patent: 5854081 (1998-12-01), Linden et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5932558 (1999-08-01), Cronstein et al.
Andersson, P., et al., "Anti-anaphylactic and anti-inflammatory effects of xanthines in the lung", Curr. Clin. Pract. Ser., , 187-192, (1985).
Berkich, D.A., et al., "Evidence of Regulated Coupling of A1 Adenosine Rececptors by Phosphorylation in Zucker Rats.", American Physiological Society, 268(4 Pt 1), E693-E704, (Apr., 1995).
Bhattacharya, S., et al., "Effects of Long-term Treatment With the Allosteric Enhancer, PD81, 723, on Chinese Hamster Ovary Cells Expressing Recombitant Human A.sub.1 Adenosine Receptors", Molecular Pharmacology, 50(1), 104-111, (Jul., 1996).
Bhattacharya, S., et al., "The Allosteric Enhancer, PD 81, 723, Stabilizes Human A.sub.1 Adenosine Receptor Coupling to G Proteins", Biochimica Biophysica Acta, 1265(1), 15-21, (Feb. 1995).
Bridges, A.J., et al., "N.sup.6 -[2-(3,5-Dimethoxyphenyl)-2-(2-Methylphenyl)-Ethyl]Adenosine and Its Uronamide Derivatives. Novel Adenosine Agonists With Both High Affinity and High Selectivity for the Adenosine A.sub.2 Receptor", Journal of Medicinal Chemistry, 31(7), 1282-1285, (1988).
Buster, B., et al., "The Effect of Adenosine Receptor Agonists on Neutrophil Pleocytosis and Blood-Brain Barrier Pathophysiology in Experimental Bacterial Meningitis", Abstract of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 37, 39, (1997).
Cembrzynska, N.M., et al., "Elevated Release of Tumor Necrosis Factor-alpha and Interferon-gamma by Bronchoalveolar Leukocytes From Patients With Bronchial Asthma.", American Review of Respiratory Disease, 147(2), 291-295, (1993).
Cothran, D.L., et al., "Ontogeny of Rat Myocardial A.sub.1 Adenosine Receptors", Biol Neonate, 68(2), 111-118, (1995).
Cristalli, G., et al., "Alkynyl Derivatives of Adenosine an Adenosine-5'-N-ethyluronamide as Selective Agonists at A.sub.2 Adenosine Receptors", Journal of Medicinal Chemistry, 35(13), 2363-2368, (1992).
Cronstein, B.N., et al., "Adenosine Modulates the Generation of Superoxide Anion by Stimulated Human Neutrophils Via Interaction With a Specific Cell Surface Receptor", Annals New York Academy of Science, 451, 291-314, (1985).
Cronstein, B.N., et al., "Adenosine; A Physiologic Modulator Of Superoxide Anion Generated By Human Neutrophils. Adenosine Acts Via An A.sub.2 Receptor On Human Neutrophils", Journal of Immunology, 135(2), 1366-1371, (1985).
Cronstein, B.N., et al., "Engagement of Adenosine Receptors Inhibits Hydrogen Peroxide (H.sub.2 O.sub.2) Release by Activated Human Neutrophils", Clinical Immunology and Immunopathology, 42(1), 76-85 (1987).
Cronstein, B.N., et al., "Methotrexate Inhibits Leukocyte Influx Into Inflammatory Sites Via The Adenosine (A.sub.2) Receptor", Clinical Research, 41(2), 244A, (1993).
Cronstein, B.N., et al., "The Adenosine/Neutrophil Paradox Resolved: Human Neutrophils Possess Both A.sub.1 and A.sub.2 Receptors That Promote Chemotaxis and Inhibits O.sub.2 Generation, Respectively", Journal of Clinical Investigation, 85(4), 1150-1157, (1990).
Cronstein, N., et al., "Occupancy of Adenosine Receptors Raises Cyclic AMP Alone And In Synergy With Occupancy Of Chemoattractant Receptors And Inhibits Membrane Depolarization", Biochemical Journal, 252(3), 709-715, (1988).
De La Harpe, J., et al., "Adenosine Regulates the Respiratory Burst Of Cytokine -Triggered Human Neutrophils Adherent To Biological Surfaces", Journal Of Immunology, 143(2), 596-602, (1989).
Dinerallo, C.A., "Interleukin-1 And Tumor Necrosis Factor: Effector Cytokines In Autoimmune Diseases", Seminars in Immunology, 4, 133-145, (1992).
Doyle, M.P., et al., "Nucleoside-induced Arteriolar Constriction: a Mast Cell-dependent Response.", American Journal of Physiology, H2042-H2050, (May, 1994).
Feoktistov, I., et al., "Adenosine A.sub.2b Receptors", The American Society for Pharmacological and Experimental Therapeutics, 49(4), 381-402 (1997).
Feoktistov, I., et al., "Role of Adenosine in Asthma", Drug Development Research, 39, 333-336, (1996).
Ferrante, A., et al., "Optimal Conditions for Simultaneous Purification of Mononuclear and Polymorphonuclear Leucocytes From Human Blood by the Hypaque-Ficoll Method", Journal of Immunological Methods, 36(2), 109, (1980).
Figler, R.A., et al., "Reconstitution of Bovine A.sub.1 Adenosine Receptors and G Proteins in Phospholipid Vesicles: .beta.Y-Subunit Composition Influences Guanine Nucleotide Exchange and Agonist Binding", Biochemistry, 36(51), 16288-16299, (1997).
Figler, R.A., et al., "Reconstitution of Recombinant Bovine A.sub.1 Adenosine Receptors in Sf9 Cell Membranes with Recombinant G Proteins of Defined Composition.", Molecular Pharmcology, 50(6), 1587-1595, (Dec. 1996).
Firestein, G.S., et al., "Adenosine Regulating Agents: A Novel Approach to Inflammation and Inflammatory Arthritis", Clinical Research, 41(2), 170A, (1993).
Francis, J.E., et al., "Highly Selective Adenosine A.sub.2 Receptor Agonists in a Series of N-Alkylated 2-Aminodenosines", Journal of Medicinal Chemistry, 34(8), 2570-2579, (1991).
Gao, Z., et al., "A.sub.2B Adenosine and P2Y.sub.2 Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells. Cross-talk Between Cyclic AMP and Protein Kinase c Pathways", Journal of Biological Chemistry, 274(9), 5972-5980, (Feb. 1999).
Gao, Z., et al., "Purification of A.sub.1 Adenosine Receptor-G-protein Complexes: Effects of Receptor Down-regulation and Phosphorylation on Coupling", Biochemical Journal, 338(Pt3), 729-736, (Mar., 1999).
Gilchrist, A., et al., "Antagonists of the Receptor-G Protein Interface Block G.sub.1 -coupled Signal Transduction", Journal of Biological Chemistry, 273(24), 14912-14919, (Jun., 1998).
Glover, D.K., et al., "Pharmacological Stress Thallium Scintigraphy With 2-Cyclohexlmethylidenehydrazinoadenosine (WRC-0470) A Novel, Short-Acting Adenosine A2A Receptor Agonist.", Circulation, 94, 1726-1732, (1996).
Griswold, D.E., et al., "Effects of Selective Phosphodieasterase Type IV Inhibitor, Rolipram, on Fluid and Cellular Phases of Inflammatory Response", Chemical Abstract, 119, Abstract No. 173828e, (1993).
Hanlon, W.A., et al., "rTNF.alpha. Facilitate Human Polymorphonuclear Leukocyte Adherence to Fibrinogen Matrices With Mobilization of Specific and Tertiary But Not Azurophilic Granule Markers", Journal of Leukocyte Biology, 50(1), 43-48, (1991).
Holmes, et al., "Restenosis After Percutaneous Transluminal Coronary Angioplasty (PTCA): A Report From the PTCA Registry of the National Heart, Lung, and Blood Institute", American Journal of Cardiology, 53, 77C-81C, (1984).
Hussain, T., et al., ".sup.125 1-APE Binding to Adenosine Receptors in Coronary Artery: Photoaffinity Labeling With .sup.125 1-azidoAPE", Journal of Pharmacology and Experimental Therapeutics, 276(1), 284-288, (Jan. 1996).
Hutchison, A.J., et al., "2-(Arylalkylamino)Adenosine-5'-Uronamides: A New Class of Highly Selective Adenosine A.sub.2 Receptor Ligands", Journal of Medicinal Chemistry, 33(7), 1919-1924, (1990).
Hutchison, A.J., et al., "CGS 21680C, an A.sub.2 Selective Adenosine Receptor Agonist With Preferential Hypotensive Activity", Journal of Pharmacology and Experimental Therapeutics, 251(1), 47-55, (1989).
Iannone, M.A., et al., "E
Jarvis William R. A.
University of Virginia
University of Virginia Patent Foundation
LandOfFree
8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human aden does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human aden, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human aden will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96453